Ceragenix Pharmaceuticals, Inc. operates as a medical device company focusing on dermatology and infectious diseases in the United States. The company has two base technology platforms, which include Barrier Repair for the treatment of dermatological disorders; and Ceragenins for the treatment of infectious disease. Its Barrier Repair technology is the platform for the development of two prescription topical creams, including EpiCeram, a prescription product for the treatment of dry skin conditions and to manage and relieve the burning and itching associated with various types of dermatoses, including eczema, irritant contact dermatitis, and radiation dermatitis; and NeoCeram, a pediatric barrier repair cream intended to create a skin barrier in premature infants and neonates. Its Ceragenin compounds are active against a range of gram positive and negative bacteria, as well as viruses, fungi, and cancers in various in vitro tests. The company uses its Ceragenin technology to formulate Cerashield antimicrobial coatings for medical devices. Ceragenix Pharmaceuticals was founded in 2002 is based in Denver, Colorado. On December 29, 2011, the voluntary petition of Ceragenix Pharmaceuticals, Inc. for reorganization under Chapter 11 was converted to Chapter 7. It had filed for Chapter 11 bankruptcy on June 2, 2010.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• No BuyIns.Net Alerts Available for CGXP